Member Info for Matml74

Trek, Great post.

I have been watching the sp patterns here for a long time, since before July 20, but the deliberate movement of the SP has been extremely obvious this month. Being on SETS on such a low volume share makes it easier, for whomever is doing this, to manipulate the SP with auto trades.

Every time this SP tries to move up a large number of shares are dumped on the ask. It has been happening for weeks. It has the effect of slowly forcing the price down to the range that the mm’s or whomever want. Now I am sure some of the selling is due to people dumping around the placing price but this doesn’t explain why all the big trades are around the same price considering the SP has varied between 140 and 200p in January.

On high volume days they let it run until the buying drys up and then they slowly force the price back down.

The real problem we have is not enough big buyers. This would put a quick stop to this. I am hoping the activ 2 start and an influx of new buyers will break this pattern next week.

Over the last few weeks I have been noticing many of our large trades tend to occur in the low 160’s so I went back and looked at the patterns since our move up from 140 range when first patient of P3 was dosed.

An interesting pattern is apparent. Since 13th Jan (P3 first dosing day)we have had 4,000,000 shares printed with price between 162 and 165. The most interesting thing though is these shares are always the largest prints of the day (80,000 plus shares). Approx 3 million of the shares were printed at 165. On the day of the Activ-2 news there were no large trades (65,000) was the largest. There were 3 x 130000 trades at 183 on they day after activ news but I believe unrelated and not included. They all appeared to buys as higher than ask at the time.

IMO there is no reason the share price should be back in the 160’s based on the news we had this week even if you include the disruption that is occurring in the market. Activ-2 is massive for the company. The share price should have reflected that. Hopefully the order clears soon and the SP will be free to find its natural level.

I guess what I am trying to say is don’t get too hung up on the daily movements in SP. There are things going on in the background that we don’t know about. Focus on fundamentals as at this point that is the only thing that matters.

It certainly does Oak.

Fauci..... "What are we going to see over the next months.....To get a direct acting antiviral agent that you could give orally.............. you need to give it for about 10 days...... We are putting in a lot of effort now..... to get the direct acting agent."

I think once Activ-2 starts and Fauci can start talking about SNG directly, this is going to blow up big time.

All the data around vaccines now is veering towards reduced efficacy with new variants and boosters required. Big pharma can’t provide annual vaccinations at cost price forever. Treatments must now become a major focus. I firmly believe the US has worked this out hence their renewed emphasis on treatments.

Ok cheers. Didn't know that.

CR its a good discussion point. The bar its set pretty low at present.

Dexamethasone

For patients on ventilators, it cut the risk of death from 40% to 28%.
For patients needing oxygen, it cut the risk of death from 25% to 20%.
----------------

Current estimates are that 15 to 20% of symptomatic cases require hospitalisation.

There has been 100 million reported cases to date. Not sure how many of these are asymptomatic but less assume 30% as this has been reported, so 70 million symptomatic cases.

Lets be conservative and say only 10% of those end up requiring hospitalisation. We have 7 million people requiring hospitalisation. Obviously these numbers will decline with vaccine uptake but at present 16% of the world's population (think we all know which countries these are) have 60% of the vaccine supply so probably not so much in the 3rd world!

Even a 10% reduction in these numbers is massive. Imagine if you had a drug that could reduce this number by 25%/50%/80%........

https://shorttracker.co.uk/company/GB00B0381Z20/

Short tracker showing it at 0% since 19th Jan.

Well said Sharesting. This company is all class and deserve to succeed fully in their advancement of SNG001.

How can any regulatory body approve something that hasn't been tested in the target group. ****ing political you are right Doc!

I am certainly not celebrating this Chris. What I find worrying about this news is the MHRA can approve a vaccine for the most vulnerable group based on data on 360 odd people in the cohort, of which both the vaccine group and the placebo group both had one case of coronavirus equating to an efficacy of 6.5%. All data needs to be made public.

The South Koreans are taking the same approach with the elderly due to the data they have been given by AZN.

FT

https://www.google.co.uk/amp/s/amp.ft.com/content/0190dae8-f751-4876-8404-68a34d9be716

“I've maintained for a while now that we have a very smart BOD, who are executing a well structured plan to get this drug exactly where it needs to be.”

Agree totally. If I ever have started to doubt the investment I just go back and review RM’s interviews and RNS’s. There is no more honest CEO on AIM in my opinion. A true professional that does not over egg anything and just states facts.

Today’s interview was probably the most confident I have seen him in any interview he has done. He is in complete control of the situation and you can tell that the path to approval is going exactly as they have planned.

GL

Might also explain why the good professor said "We know it works" in the sky interview. We know form his November interview he tends to drop little hints.

As it was double blinded and not triple blinded trial this certainly is a possibility Scinv!

Biden spending $50 billion on covid testing and this test will be taking part of that through this agreement with one of the big players.

Brilliant. Patience wins the day. This is huge for this company. Biden spending 50 billion on covid testing in the US and little old gendrive now right in the mix of that with one of the biggest players in the market.

Be great to hear your thoughts Bigsexy when you have time.

Tony, It was a coin flip May/June time last year and that was the way I considered my investment at that point. Odds are much more in favour of the shareholder at this point due to the understanding of interferon response in relation to copied disease progression, how far the company has come in terms of trials and their progression, planned manufacturing upscaling and the data that has been generated both in the lab and in the P2 trial.

Thanks Dafad. It's clear SNG001 is now on everyone's radar. Now just need positive data.